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Abstract
Background
Genome-wide association studies (GWAS) have identified several loci associated with schizophrenia and/or
bipolar disorder. We performed a GWAS of psychosis as a broad syndrome rather than within specific
diagnostic categories.
Methods
1239 cases with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder; 857 of their
unaffected relatives, and 2739 healthy controls were genotyped with the Affymetrix 6.0 single nucleotide
polymorphism (SNP) array. Analyses of 695,193 SNPs were conducted using UNPHASED, which
combines information across families and unrelated individuals. We attempted to replicate signals found in
23 genomic regions using existing data on nonoverlapping samples from the Psychiatric GWAS
Consortium and Schizophrenia-GENE-plus cohorts (10,352 schizophrenia patients and 24,474 controls).
Results
No individual SNP showed compelling evidence for association with psychosis in our data. However, we
observed a trend for association with same risk alleles at loci previously associated with schizophrenia
(one-sided p = .003). A polygenic score analysis found that the Psychiatric GWAS Consortium’s panel of
SNPs associated with schizophrenia significantly predicted disease status in our sample (p = 5 × 10 ) and
explained approximately 2% of the phenotypic variance.
Conclusions
Although narrowly defined phenotypes have their advantages, we believe new loci may also be discovered
through meta-analysis across broad phenotypes. The novel statistical methodology we introduced to model
effect size heterogeneity between studies should help future GWAS that combine association evidence from
related phenotypes. Applying these approaches, we highlight three loci that warrant further investigation.
We found that SNPs conveying risk for schizophrenia are also predictive of disease status in our data.
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psychosis, schizophrenia
Psychotic disorders including schizophrenia, bipolar disorders, and schizoaffective disorders affect
approximately 3% of the general population (1–6) and constitute the most severe forms of mental diseases.
Characteristic symptoms include hallucinations, delusional beliefs, and severe mood variations and
cognitive impairments, all of which can lead to major changes in behavior and ability to function.
According to the World Health Organization’s World Health Report, these psychotic disorders are ranked
within the top seven leading causes of disability in young adults (7).
The genetic architecture of schizophrenia and bipolar disorder has been shown to include common alleles
of subtle effect and rare mutations of large effect, often involving genome copy number variation (8–11).
Recent large-scale meta-analyses of schizophrenia (12), conducted by the Psychiatric GWAS Consortium
(PGC), combined data from more than 50,000 individuals from 17 international cohorts (13–25) and
identified seven associated loci. Of these loci, five were new, and two had been previously implicated. The
strongest new finding in schizophrenia was within an intron of a putative primary transcript for MIR137
(microRNA 137), a known regulator of neuronal development. Four other schizophrenia loci with strong
statistical support contain predicted targets of MIR137, suggesting MIR137-mediated dysregulation as a
previously unknown etiologic mechanism in schizophrenia. The meta-analysis (12) also confirmed the role
of the major histocompatibility complex (MHC) region, as suggested in other studies (23,24,26,27), as well
as a marker in intron four of transcription factor 4 (TCF4) (24).
The PGC conducted a similar meta-analysis for bipolar disorder (28) including more than 11,000 cases and
51,000 controls from previous association studies (15,29–41). The analysis confirmed an association with
CACNA1C and identified a new intronic variant in ODZ4. An overlap in the polygenic component between
schizophrenia and bipolar disorder was also found (42,43). In a combined meta-analysis of both
schizophrenia and bipolar disorder, three loci reached genome-wide significance: CACNA1C, ANK3, and
the ITIH3-ITIH4 region (28).
As data accumulate, there is increasing evidence for overlap in the genetic component to risk between
different psychiatric disorders (44–46). When combined with epidemiologic and neuroimaging data
(47–50), the shared genetic architecture supports the view of schizophrenia, bipolar disorder, and other
psychoses as related rather than etiologically distinct entities (8,12,28,46,51–59). Motivated by these
findings, we performed a genome-wide association study (GWAS) of psychotic disorders including patients
with schizophrenia, schizoaffective disorder, and bipolar disorder with a history of psychotic symptoms.
Methods and Materials
The Cohort
Before any exclusion, the full data set included 6935 participants with 1820 patients, 1224 of their
unaffected relatives, and 3891 healthy control subjects. These samples were collected through seven centers
across Australia and Europe (Germany, Holland, Spain, and United Kingdom). Participants provided
written informed consent, and the study was approved by the respective ethical committees at each of the
seven participating centers. After quality control, the full sample included 4835 participants of which 1239,
857, and 2739 were patients, their unaffected relatives, and healthy control subjects, respectively.
Additional sample and center details are provided in Table S1 of Supplement 1.
Inclusion and Exclusion Criteria and Phenotype Definition
To allow for a DSM-IV (60) diagnosis to be ascertained or ruled out, all participants (including controls and
unaffected family members) underwent a structured clinical interview with either the Schedule for
Affective Disorders and Schizophrenia or the Structured Clinical Interview for DSM Disorders, or the
Schedules for Clinical Assessment in Neuropsychiatry (61–63). Of the cases passing quality control, 784
met criteria for schizophrenia, 113 for bipolar disorder with a history of psychotic symptoms, 110 for
psychotic disorder not otherwise specified, 97 for schizophreniform disorder, 64 for schizoaffective
disorder, 44 for brief psychotic disorder, 20 for delusional disorder, and 7 for substance-induced psychosis.
A Genome-wide Association Analysis of a Broad Psychosis ... http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923972/?rep...
2 of 25 19-12-15 01:55
Participants in all groups were excluded if they had a history of neurologic disease or head injury resulting
in loss of consciousness.
DNA Sample Preparation
Genomic DNA obtained from blood for all participants was sent to the Wellcome Trust Sanger Institute,
Cambridge, United Kingdom. Samples were processed in 96-well plate format and each plate carried a
positive and a negative control. DNA concentrations were quantified using a PicoGreen assay (Invitrogen,
Life Technologies, Grand Island, New York) and an aliquot assayed by agarose gel electrophoresis. A
sample passed quality control if the original DNA concentration was at least 50 ng/µL and the DNA was
not degraded.
Genotyping Methodology and Quality Control
To track sample identity, 30 single nucleotide polymorphisms (SNPs) including sex chromosome markers
were typed on the Sequenom platform before entry to the whole genome genotyping pipeline. Of the initial
6935 samples, 347 failed quality control due to degraded or insufficient DNA or incorrect sex
classification. The remaining samples were sent for genotyping with the Genome-wide Human SNP Array
6.0 at Affymetrix Services Lab (http://www.affymetrix.com).
Data Quality Control
See Tables S2 and S3 in Supplement 1. Genotype calling was conducted using the CHIAMO algorithm
(64,65) modified for use with the Affymetrix 6.0 genotyping array. We excluded 11,610 SNPs with a
study-wide missing data rate over 5%. We removed 26,858 SNPs with four or more Mendelian inheritance
errors identified with Pedstats (66). Additional exclusion criteria were departure from Hardy-Weinberg
equilibrium (p < 10 ) or minor allele frequency (MAF) <.02 with 2404 and 145,097 SNPs removed,
respectively. A total of 38,895 SNPs from the X or Y chromosomes or mitochondrial DNA were also
excluded from the analysis. Finally, 9499 poorly genotyped SNPs were removed following visual
inspection of the genotyping intensity plots in the program Evoker (67).
We excluded 214 samples with more than 2% missing data across all SNPs. Another 70 samples were
excluded due to divergent genome-wide heterozygosity (inbreeding coefficients were F > .076 or F < −.076
as estimated with PLINK (42). Chromosomal sharing was inferred from a genome-wide subset of 71,677
SNPs and from each duplicate pair the sample with the most complete genotype data was kept. We
removed 70 duplicates and monozygotic twins by excluding one of each pair of individuals showing
identity by descent greater than 95%.
After quality control, 4835 individuals remained. Initial analysis of the genotype data identified a high
fraction of samples (approximately 30%), which showed poor signal-to-noise ratio in the genotyping assay.
Because the experimental source of the problem was unclear and to ensure a robust set of genotype calls,
these samples were removed from further analysis. We note that the sample loss was randomly distributed
across the three clinical groups (32% of patients, 30% of relatives, and 30% of controls; χ  (2 df) = 3.2; p =
.20). Full details on the sample quality control are provided in Table S2 of Supplement 1.
In addition to 3490 unrelated individuals, there were 1345 related individuals clustered in 462 families. The
family size ranged between 2 and 5 with an average of 2.9 members. Of the families, 196 were control
families, 243 had one affected case only, 21 families included two cases, and another 2 families had three
cases. Data from these individuals were analyzed at 695,193 autosomal SNPs.
Population Structure Analysis
To investigate the genetic structure in the data, we performed principal component (PC) analysis (PCA) of
unrelated individuals using EIGENSOFT version 3.0 (68) on a thinned set of SNPs (see Methods and
Materials in Supplement 1). Owing to the multicenter nature of our study, we assessed the need to include
PCs as covariates in statistical tests of association to control for population stratification (69). This was
done by using PLINK (42) to calculate the genome-wide distribution of the association test statistic in the
unrelated individuals using different numbers of PCs as covariates. Possible inflation in the test statistic
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was measured by the genomic control parameter λ, which is the ratio of the median of the observed test
statistic distribution to that of its expectation under the null hypothesis (70).
Association Analysis in Our Discovery Sample
A genome-wide association analysis was conducted with UNPHASED v3.1.4. (71), which allows a
combined analysis of both families and unrelated individuals, thus increasing statistical power.
UNPHASED calculates separately the transmitted and untransmitted alleles in families as well as the allelic
frequencies in unrelated patients and controls, giving a combined odds ratio, 95% confidence interval, and
p value. The analysis included three PCs as covariates.
For SNPs showing association with psychosis in our data with p < 1 × 10 , proxy SNPs were identified
using the proxy report routine in PLINK (42). Only those SNPs that were in linkage disequilibrium (r  ≥ .5)
with and within 100-kb distance from at least one such proxy SNP that showed association with psychosis
with p < 1 × 10  were selected for the replication phase. These criteria reduced the possibility that the
association signal was driven by an artifact at the most associated SNP.
We attempted to replicate 44 SNPs included in the catalogue of published GWAS (72), accessed in January
2012, for schizophrenia or bipolar disorder with p values less than 1 × 10 . These SNPs and the studies
that identified them are listed in Table 1. If a reported SNP was not genotyped directly in our data, we used
the 1000 Genomes Project (73) data to identify the best tag (highest r ) and orientated the haplotype to the
risk allele so that the directions of the odds ratios were matched between our analysis and the previous
studies. Where relevant information was not available, the SNP was excluded from analysis.
Related Effects Meta-Analysis
We attempted in silico replication with independent samples from the PGC and the SGENE+ consortia
using both a fixed effects meta-analysis (42) and a Bayesian related effects approach (27). The Bayesian
related effects model (see Methods and Materials in Supplement 1) was considered appropriate in this
context because there are obvious sources of heterogeneity between the discovery and the replication
datasets due to differing phenotype definitions and sample origins. To ensure that no samples were
overlapping between the discovery and replication data sets, we used a subset of at least 13,000 SNPs to
exclude 717 participants (51 cases, 642 controls, 24 relatives) from our primary study. Similarly, another 74
control subjects were excluded from the SGENE+ replication cohort. Only SGENE+ samples that were not
part of the PGC study were included in our meta-analyses.
Polygenic Score Analysis
A polygenic score analysis was conducted using a thinned (on the basis of linkage disequilibrium) panel of
113,774 SNPs from the PGC-schizophrenia meta-analysis. Of these SNPs, 72,635 were available in our
data, and we further added suitable proxies for another 19,434 SNPs, which were identified through the
program SNAP (75) to have r  > .9 with the index SNP and to be within 500-kb distance. Of 4835 samples
passing the above described quality control filters we excluded 717 individuals that overlapped with the
PGC sample and another 833 related participants. Therefore, our polygenic analysis was based on a subset
of 3285 unrelated subjects comprising of 1188 patients and 2097 controls. The polygenic score for each
individual was calculated from the number of risk alleles they carried for each SNP, weighted by the
log(OR) provided by the PGC, and summed across all the SNPs. Calculations were performed using the
PLINK SNP scoring routine (42).
We used logistic regression, with the three population structure PCs and the center of origin of the samples
as covariates, to test whether the polygenic scores were predictive of case–control status in our study.
Following Purcell et al. (26), we reported the proportion of the variance of disease risk in our sample (as
measured by Nagelkerke’s pseudo-R ) that could be explained by the panel of SNPs. We examined the
proportion of the variance explained by our data at various p value thresholds for the PGC-schizophrenia
SNP list (p < .01, .05, .1, .2, .3, .4, and .5) (26,43).
Results
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The primary goal of our study was to use published GWAS data in schizophrenia and bipolar disorder to
facilitate discovery in a new sample with a broad psychosis phenotype. First, we examine previously
published loci in our data set. We then present our discovery association data followed by replication in
independent samples, using a novel meta-analysis approach. Finally, we report a polygenic score analysis
testing whether a panel of SNPs associated specifically with schizophrenia are predictive of the broader
phenotype in our sample.
Population Structure
Analysis of our data via PCA showed that the major components of the genetic variation capture the
geographic origin of the samples (Figure S1 in Supplement 1). The first PC separates samples from
northern Spain (Santander) from the rest of the sample. We found it necessary to include the first three PCs
as covariates to control for the confounding effects of population structure even though this may reduce
power to detect associations. The genomic control parameter, λ, was equal to 1.030 and 1.374 with and
without including the three PCs respectively.
Replication of Previously Published Loci in Our Data Set
To ascertain the strength of association in our data at loci previously associated with schizophrenia and/or
bipolar disorder, we systematically assessed the evidence at the SNPs most strongly correlated with the
previously reported SNPs and their risk alleles (Table 1; Figure 1)
(12,15,21,23,24,26,28,30,33,34,37,38,66,76–96). We observed evidence for association at several loci.
These include multiple SNPs in the MHC region, most strongly at rs9272219 near HLA-DQA1. We also
replicated association at MIR137, MCTP1, NRGN, and CDC68. More generally, we observed a positive
correlation between previously reported effect sizes and those estimated here, most notably with
schizophrenia associated loci where 19 of the 24 loci had the same risk allele (one-sided p = .003). We note
that this sign test remained significant (p < .05) after thinning to reduce correlation between SNPs and
removing the SNPs within the MHC (Table S4 in Supplement 1).
Association Analysis in Our Discovery Sample
We did not identify any novel SNPs associated with psychosis as a broad phenotype with p < 1 × 10  from
our data set. Figure 2 and Figure S2 in Supplement 1 show respectively the quantile-quantile plots of the
distribution of observed and expected p values and the Manhattan plot of all autosomal SNPs that passed
quality control.
Independent Replication of Our Discovery Data
We selected 63 SNPs in 23 genomic regions (Supplementary Data in Supplement 1) showing the strongest
evidence for association in our discovery dataset (p < 1 × 10 ) and having at least one suitable proxy SNP
also associated (see Methods and Materials). We then attempted in silico replication using the large
independent (see Methods and Materials) data sets publicly available from the PGC (51,57,97,98) as well
as with data provided by the SGENE+ Consortium (24,25).
All of the selected 63 SNPs were present in at least one of the replication data sets, and 53 SNPs were
available in both collections giving a two-study independent replication data set with 10,352 patients and
24,474 control subjects. By combining estimates of the logarithmic odds ratios weighted by their precision
(i.e., inverse variance of the estimator) across discovery and replication cohorts, we conducted a
three-study meta-analysis with 11,540 patients, 833 of their unaffected relatives, and 26,571 control
subjects. Table 2 contains the SNPs that in the replication data showed an effect in the same direction (with
one-sided p < .05) as in the discovery data set and had either combined (discovery plus replication) fixed
effects p value < 10  or combined fixed effects or related effects Bayes factor >100. Regional association
plots of these SNPs are included in Figure 3 and forest plots are given in Figure S3 in Supplement 1. Full
details of the replication meta-analyses are presented in Supplement 1.
Two of five top regions in our discovery analysis, rs743393 (on chromosome 3) and rs968794 (on
chromosome 7), showed effects in the same direction in the replication data with one-sided replication p
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values of .020 and .007, respectively. However, the combined fixed effects evidence of association at these
loci is weak by the standards of GWAS (p values 7 × 10  and 8 × 10 , and Bayes factors 25 and 200,
respectively). Bayes factors from the related effects model (440 and 7400, respectively), which allow
heterogeneity in effect size across studies, are larger than those from the fixed effect model but still fail to
provide convincing levels of evidence for these associations. See Wellcome Trust Case Control Consortium
(66) for interpreting Bayes factors in the GWAS context.
Polygenic Score Analysis
We performed a polygenic score analysis using the SNPs associated with schizophrenia in the PGC study.
Logistic regression analyses showed significantly higher scores for patients than control subjects (p = 5 ×
10 ), and explained approximately 1.7% of Nagelkerke’s pseudo-variance in our sample. For additional
results on the polygenic component, see Methods and Materials and Figure S4 in Supplement 1.
Discussion
Although extensive twin research has shown high heritability estimates ranging between 73% and 85% for
schizophrenia, schizoaffective disorder, and manic syndromes (99–103), compared with other
neuropsychiatric diseases, the search for psychosis susceptibility genes has not been straightforward
(104–110). Several loci have now been convincingly identified, and more are expected to be found through
the PGC, a large international collaboration undertaking mega-analyses of the available data (8,12,28). In
this context, our sample with 4835 participants has modest power to detect new variants unequivocally
(111), and thus it is not that surprising that we did not identify convincing novel associations with a broad
psychosis phenotype. For example, our data provide less than 10% power at type I error of 1 × 10  for an
allelic relative risk of 1.2 at a common SNP, and in practice power may be further reduced because of our
broader disease phenotype and our use of PC covariates to control for population structure. It has been
estimated that for allelic odds ratios of 1.1 and 1.2 as many as 10,000 to more than 20,000 subjects would
be required to achieve 80% power at genome-wide significance levels (112). We hope that our data set will
be valuable in the future meta-analyses that are likely to identify further common variants for psychotic
illnesses with convincing statistical evidence.
The loci for which we found the best evidence of association, given our data and the independent
replication samples from the PGC and SGENE+ consortium, are reported in Table 2 and their regional
association plots are in Figure 3. These include rs743393 located in chromosome 3, which is near the
Integrin alpha 9 gene (ITGA9), thought to codify for a membrane glycoprotein that mediates cell-cell and
cell-matrix adhesion (22). SNP rs968794 in chromosome 7 is close to the NDUFA4 gene coding for a
protein that is involved in the mitochondrial membrane respiratory chain (23). Finally, rs4761708 is located
in a gene desert in chromosome 12 flanked by recombination hotspots. Limited information is available on
the role of these genes and whether they are causal in increasing the risk of developing psychosis.
Additional data are required to confirm the associations and to inform on underlying disease mechanisms.
Although our sample was too small to identify new loci unequivocally, it had good power to replicate
previously published signals with modest effects assuming they are consistent across psychosis phenotypes.
The analysis of established schizophrenia loci shows that there is a trend for consistent association in our
data (Figure 1). Also the polygenic score analysis showed that, compared with control subjects, our cases
are enriched for alleles thought to convey risk for schizophrenia; the PGC’s panel of SNPs significantly
predicted case–control status in our study and explained around 2% of the phenotypic variance in our
sample. This is comparable to previously reported figures in other European case–control and family-based
populations (26,43) and is consistent with a highly polygenic model of disease risk. Larger data sets are
required to determine whether these signals are specific to only some of the subphenotypes of psychosis or
are present across them.
Schizophrenia and bipolar disorder are thought to be highly complex and polygenic, with potentially
thousands of susceptibility genes of small effect and, particularly for schizophrenia, also with rare variants
of larger effects (10,14,26,52,58,107,110–113). Previous GWAS have generally targeted a specific
diagnostic category, and the merit of analyzing a psychosis spectrum is debatable. One of the challenges
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facing psychiatric genetics has been the heterogeneity of the diseases in question and studying a broader
phenotype could exacerbate this problem. However, as GWAS data accumulate, there is growing evidence
of genetic overlap between schizophrenia and bipolar disorder (8,12,28,44,46,51,55,56,58–60). Therefore,
in addition to examining narrowly defined diseases it is of use to undertake cross-disorder analyses. Our
replication of established schizophrenia hits in a broadly defined psychosis sample and polygenic analyses
support this view.
Current benchmarks for establishing new associations usually insist on a combined discovery and
replication p value of less than 5 × 10  using a fixed effects meta-analysis, which is the correct summary
of the overall statistical evidence when the true effect size is exactly the same across the studies. However,
when the effect size may genuinely differ between the studies due to, for example, differences in phenotype
definition, patterns of linkage disequilibrium or environmental contributions, it is appropriate to assess
association evidence with a model that allows for heterogeneity. Here we have used a Bayesian related
effects model that assumes that the effects between the studies are similar (e.g., highly correlated on the log
odds scale) but not necessarily the same. A computational advantage of this model is that it only requires
the studywide summary statistics (effect size and its standard error), and therefore we believe it will be
useful in future meta-analyses of existing GWAS data sets, for example, across neuropsychiatric diseases.
In our study, we applied the related effects model to combine the discovery and replication results at 63
SNPs that had the most evidence in the discovery analysis. As expected, the related effects model assigns a
higher probability than the fixed effects model to the event that these SNPs represent real associations
(Supplement 1). For any one SNP, this can be either because the association is a true positive but
heterogeneous and/or subject to a “winner’s curse” effect (114,115) or because the association is a false
positive and appears heterogeneous because of a relatively strong discovery signal created by chance
effects. Future studies are needed to determine conclusively whether the SNPs reported in Table 2 and
Figure 3 represent real associations.
The scenario described here in which a discovery analysis of a particular phenotype in a small sample
attempts to replicate putative associations in silico, in much larger meta-analyses of similar phenotypes, is
likely to become more common in human genetics as GWAS data accumulate. We note that stringent p
value thresholds for combined discovery and replication meta-analysis make it challenging to identify new
loci because loci with consistent effects across studies will have already been identified. Therefore, an
ongoing genome-wide meta-analysis across related phenotypes modeling effect heterogeneity where
appropriate is arguably the most powerful approach to identify additional susceptibility loci.
In conclusion, although no individual SNPs reached convincing evidence of association with psychosis, our
data contribute to the international effort to produce a cohort large enough to investigate both the shared
and separate genetic bases of multiple psychotic disorders. Our polygenic score analysis indicates that the
PGC-derived panel of SNPs conveying risk specifically for schizophrenia is also predictive of case–control
status in our data, explaining around 2% of the phenotypic variance. We advocate the use of related effects
models in large meta-analyses for summarizing the evidence for association across independent studies of
related phenotypes.
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Figure 1
Replication of previously published associated schizophrenia (SCZ) and bipolar disorder (BPD) loci. Reported odds ratios
from the literature (x axis) plotted against the odds ratios estimated from our data as listed in Table 1 (y axis). The dotted
line indicates an odds ratio of 1 in our data. Points above the line indicate the same direction of effect in previous studies
and our data. Black circles indicate single nucleotide polymorphisms that replicate (p one-sided < .05) in our study.
Triangles denote single nucleotide polymorphisms within the major histocompatibility complex region. Sign tests for an
enrichment of effect in the same direction are presented for loci previously associated with schizophrenia, bipolar disorder,
or both. Additional details on the sign tests are available in Table S4 of Supplement 1.
A Genome-wide Association Analysis of a Broad Psychosis ... http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923972/?rep...
19 of 25 19-12-15 01:55
Figure 2
Quantile-quantile plots of the distribution of observed and expected p value at all autosomal single nucleotide
polymorphisms passing quality control. The genomic control lambda value was 1.03. This represents analyses conducted
on our entire discovery sample (n = 4835).
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Figure 3
Regional association plots for the three single nucleotide polymorphisms (SNPs) reported in Table 2. The plots show the
evidence of association in our discovery data at genotyped SNPs. The SNP listed in Table 2 is indicated with a diamond,
and flanking SNPs (circles) are colored according to their correlations (r ) with this SNP measured in HapMap. CEU, Utah
residents (CEPH) with Northern and Western European ancestry.
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Table 1
Evidence in Our Discovery Data at Loci Previously Reported to Be Associated with SCZ and/or BPD
Chr Position
(b36)
Genes SNP Risk
Allele
OR Phen Previous
Studies
Best Tag r  1000
Genomes
Freq p Value
(Two-Sided)
1 98502934 MIR137 rs1625579-T 1.12 SCZ (12) rs1782810 .975 .8034 .0641257
1 167903079 BRP44,
DCAF6
rs10489202-A 1.23 SCZ (21) rs10489202 1.000 .2312 .310317
1 243608967 — rs6703335-G 1.09 SCZ (12) rs6703335 1.000 .4324 .476216
2 58222928 VRK2 rs2312147-C 1.09 SCZ (24,75) rs1518395 1.000 .6172 .740698
2 193984621 PCGEM1 rs17662626-A 1.2 SCZ (12) rs17666314 .633 .942 .810016
3 36862980 — rs4624519-T 1.09 SCZ (12) rs4624519 1.000 .6264 .709072
3 52821011 ITIH1, NEK4 rs1042779-A 1.19 BPD (38,76) rs1042779 1.000 .6237 .357295
3 52855229 ITIH3, ITIH4 rs2239547-T 1.1 SCZ (12) rs1573815 .786 .7678 .283078
3 180550702 FXR1 rs6782299-T 1.1 SCZ (26) rs6782299 1.000 .7294 .822086
4 103457418 NFKB1 rs230529-T 1.45 SCZ (77) rs230529 1.000 .3895 .363959
5 94154588 MCTP1 rs17418283-C 1.21 BPD (38) rs255339 .834 .2968 .0838988
6 27143883 MHC rs13194053-T 1.22 SCZ (23,26) rs7745603 .866 .7697 .103731
6 27248931 MHC rs6932590-T 1.16 SCZ (24,26,78,79) rs6938200 .874 .7947 .219974
6 28227604 MHC,NKAPL rs1635-G 1.28 SCZ (80) rs2299030 .909 .03693 .265435
6 30174131 MHC,TRIM26 rs2021722-C 1.15 SCZ (12) rs2517611 1.000 .8058 .418896
6 32172993 MHC,
NOTCH4
rs3131296-G 1.19 SCZ (24,78) rs2071278 1.000 .8534 .61264
6 32602269 MHC,
HLA-DQA1
rs9272219-G 1.14 SCZ (23) rs9272219 1.000 .7105 .0740771
6 89732101 GABRR1 rs12201676-C 1.31 SCZ,
BPD
(81) rs12201676 1.000 .2452 .211557
7 145959243 CNTNAP2 rs802568-C 2.03 SCZ,
BPD
(81) rs802568 1.000 .02746 .197092
7 156048649 LOC393076 rs10949808-T 1.27 SCZ,
BPD
(81) rs10949808 1.000 .397 .224947
8 4180844 CSMD1 rs10503253-A 1.16 SCZ (12) rs10103330 1.000 .1993 .807814
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Chr Position
(b36)
Genes SNP Risk
Allele
OR Phen Previous
Studies
Best Tag r  1000
Genomes
Freq p Value
(Two-Sided)
8 38031345 LSM1,
WHSC1L1
rs16887244-A 1.19 SCZ (21) rs16887244 1.000 .7614 .436771
8 58840924 FAM110B rs1992045-T 1.56 SCZ,
BPD
(81) rs1992045 1.000 .07363 .125349
8 89760311 MMP16 rs7004633-A 1.11 SCZ (12,82) rs7005110 1.000 .1925 .914021
9 121359286 ASTN2 rs11789399-G 1.29 SCZ,
BPD
(81) rs11789399 1.000 .4962 .415783
10 62179812 ANK3 rs10994336-T 1.45 BPD (33,38,83–86) rs3808943 .858 .05389 .209758
10 62279124 ANK3 rs10994397-T 1.22 BPD (28) rs3808943 .858 .05389 .209758
10 104775908 CNNM2 rs7914558-G 1.22 SCZ (12,87) rs10509757 1.000 .5927 .131729
10 104906211 NT5C2 rs11191580-T 1.2 SCZ (12,87) rs11191580 1.000 .9169 .912034
11 17160148 — rs4356203-G 1.09 SCZ (12) rs4356203 1.000 .4236 .342312
11 66551002 Multiple rs10896135-G 1.12 BPD (28) rs4930390 1.000 .2557 .901194
11 79077193 ODZ4 rs12576775-G 1.14 BPD (28) rs7932890 1.000 .1737 .259849
11 98125404 CNTN5 rs2509843-C 1.27 SCZ,
BPD
(81) rs2848547 1.000 .3711 .400322
11 124606285 NRGN rs12807809-T 1.15 SCZ (24,80,89) rs1939214 .972 .8282 .0051205
12 2345295 CACNA1C rs1006737-A 1.18 SCZ,
BPD
(15,33,37,38,90) rs1006737 1.000 .3265 .353821
12 2419896 CANCNA1C rs4765913-A 1.14 BPD (28) rs4765914 .935 .8061 .432068
13 42653437 DGKH rs1012053-A 1.59 BPD (91–93) rs1170188 .806 .8133 .26017
13 106651661 DAOA rs4996815-C 1.28 SCZ,
BPD
(82) rs4996815 1.000 .3576 .737436
15 38995491 Multiple rs12899449-A 1.2 BPD (33) rs12899449 1.000 .7063 .441365
16 23634026 Multiple rs420259-A 2.08 BPD (34,66,94,95) rs420259 1.000 .7306 .517701
18 52752017 CCDC68 rs12966547-G 1.4 SCZ (12) rs11874716 1.000 .567 .0379359
18 53058238 TCF4 rs17594526-T 1.44 SCZ (26) rs17594526 1.000 .0321 .915797
19 19361735 NCAN rs1064395-A 1.17 SCZ,
BPD
(30,96) rs1064395 1.000 .1639 .543254
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Chr Position
(b36)
Genes SNP Risk
Allele
OR Phen Previous
Studies
Best Tag r  1000
Genomes
Freq p Value
(Two-Sided)
20 19852503 RIN2 rs6046396-G 1.28 SCZ,
BPD
(82) rs6046396 1.000 .3015 .57124
Evidence for association at the best marker, as measured by correlation (r ) in the 1000 Genomes Project
data (74), of previously implicated loci. Where the previously reported single nucleotide polymorphism
was not typed in our data, we oriented the haplotypes to estimate the odds ratio for the risk allele allowing a
one-sided comparison.
BPD, bipolar disorder; Chr, chromosome; CI, confidence interval; Freq, frequency; OR, odds ratio; Phen,
phenotype; SCZ, schizophrenia.
One-sided p < .05 (for replication with the same risk allele).
2
2
a
A Genome-wide Association Analysis of a Broad Psychosis ... http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923972/?rep...
24 of 25 19-12-15 01:55
Table 2
Loci Where the Strongest Evidence of Association Was Found
Chr
SNP (Risk
Allele)
Position
(Build 36)
Discovery p OR
(95% CI)
Replication p OR
(95% CI)
Combined p OR
(95% CI)
log10BF
Same
log10BF
Related
3 rs743393-C 37718972 9.40E-06 .039 7.40E-04 1.43 2.64
1.301
(1.157–1.462)
1.043
(1.002–1.085)
1.067
(1.028–1.108)
7 rs968794-A 10856010 8.30E-07 .014 8.40E-05 2.3 3.87
1.324
(1.184–1.480)
1.050
(1.010–1.091)
1.076
(1.037–1.116)
12 rs4761708-C 92276217 1.40E-04 .024 6.40E-04 1.56 2.18
1.291
(1.130–1.476)
1.058
(1.007–1.110)
1.083
(1.034–1.133)
Evidence of association across the discovery sample and the Psychiatric GWAS Consortium and SGENE
replication collections as also shown as a forest plot in Figure S3 in Supplement 1. We report p values, ORs
(and 95% CIs) for these cohorts and the combined evidence (using an inverse variance weighted fixed
effects approach). We also show the log10BF for models assuming effects to be either the same (fixed) or
related (allowing heterogeneity). Note that the discovery sample ORs and p values presented in this table
are based on a subset of our sample that did not overlap with the replication cohorts; therefore, the p values
may vary from those presented in Figure S2 in Supplement 1, which includes our entire discovery data set.
BF, Bayes factor; Chr, chromosome; CI, confidence interval; OR, odds ratio; SNP, single nucleotide
polymorphism.
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